Efficacy and Safety of Secondary Prophylactic Versus On-Demand Sucrose-Formulated Recombinant Factor VIII Treatment in Adults with Severe Hemophilia A: Results from a 13-Month Crossover Study

被引：0

|

作者：

Collins, Peter ^{[1
]}

Faradji, Albert ^{[2
]}

Morfini, Massimo ^{[3
]}

Enriquez, Monika Maas ^{[4
]}

Gorina, Eduard ^{[5
]}

Schwartz, Lawrence ^{[6
]}

Lemm, Georg ^{[5
]}

机构：

[1] Univ Wales Hosp, Cardiff CF4 4XW, S Glam, Wales

[2] Hautepierre Hosp, Strasbourg, France

[3] Univ Hosp, Florence, Italy

[4] Bayer HealthCare, Wuppertal, Germany

[5] Bayer HealthCare Pharmaceut, Berkeley, CA USA

[6] Bayer HealthCare Pharmaceut, Montville, NJ USA

来源：

BLOOD | 2008年 / 112卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：194 / 195

页数：2

相关论文

共 33 条

[31] The prolong-ate study: a phase 2/3 study to evaluate efficacy and safety of bax 855, a longer-acting pegylated full-length recombinant factor VIII (PEG-RFVIII), for prophylaxis and treatment of bleeding in severe hemophilia A
Sorensen, B.
Singer, J.
Fritsch, S.
Ewenstein, B.
Wong, W. Y.
HAEMOPHILIA, 2013, 19 : 39 - 39
[32] Pharmacokinetics, Safety and Preliminary Efficacy of Multiple Doses of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW117) in Previously Treated Adult and Adolescent Subjects with Severe Hemophilia a: Results from an OpenLabel, Multicenter, Phase 2 Study
Xue, Feng
Chen, Weizhi
Guo, Shuxia
Hua, Haiying
Cao, Yu
Feng, Xianqi
Yang, Renchi
BLOOD, 2023, 142
[33] Achievement of Normal Circulating Factor VIII Activity Following Bmn 270 AAV5-FVIII Gene Transfer: Interim, Long-Term Efficacy and Safety Results from a Phase 1/2 Study in Patients with Severe Hemophilia a
Pasi, K. John
Rangarajan, Savita
Kim, Benjamin
Lester, Will
Perry, David
Madan, Bella
Tavakkoli, Fatemeh
Yang, Ke
Pierce, Glenn F.
Wong, Wing Yen
BLOOD, 2017, 130

← 1 2 3 4 →